Sarcoma cells engineered to secrete IFN-γ or IL-2 acquire sensitization to immune cell killing via different mechanisms

Cytokine

Volumn 9, Issue 5, 1997, Pages 328-332

  Flemming, Claudia L ^a   Patel, Poulam M ^a   Box, Gary ^a   Eccles, Suzanne A ^a   Collins, Mary K L ^a  

^a NONE

Author keywords

Extracellular matrix; IFN ; IL 2; MHC

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL KILLING; CELL SECRETION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROSARCOMA; IMMUNOCOMPETENT CELL; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SUPERNATANT;

ANIMALIA; MURINAE;

EID: 0031149968     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0172     Document Type: Article

References (25)

1. 1. Collins MKL (ed.) (1994) Gene therapy. Seminars in Cancer Biology 5.
2. 2. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403.
3. 3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224.
4. 4. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard E (1991) Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 21:851-854.
5. 5. Russell S, Eccles S, Flemming C, Johnson C, Collins M (1991) Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 47:244-251.
6. 6. Chen P, Ananthaswamy H (1993) Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 151:244-255.
7. 7. Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mule JJ, Rosenberg SA (1993) Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol 150:896-908.
8. 8. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E-I, Taniyama T, Sakata T-A (1989) Exogenous expression of mouse Interferon γ-cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86:9456-9460.
9. 9. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K., and Gilboa, E. (1990) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820-7825.
10. 10. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G (1992) Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 149:3627-3635.
11. 11. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J Immunol 150:1458-1470.
12. 12. Bannerji R, Arroyo C, Cordon-Cardo C, Gilboa E (1994) The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152:2324-2332.
13. 13. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L (1993) Anti-metastatic vaccination of tumour-bearing mice with IL2 gene-inserted tumour cells. Int J Cancer 53:471-477.
14. 14. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladder tumours in mice treated with IL2 gene-modified cells. J Exp Med 177:1127-1134.
15. 15. Rosenthal, F., Cronin, K., Bannerji, R., Golde, D., and Gansbacher, B. (1994) Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 83:1289-1298.
16. 16. Patel P, Flemming C, Russell S, McKay I, MacLennan K, Box G, Eccles S (1993) Comparison of the potential therapeutic effects of IL2 or IL4 secretion by a single tumour. Br J Cancer 68:295-302.
17. 17. Patel PM, Flemming CL, Russell SJ, Eccles SA, Collins MKL (1993) Cytokine gene transfer as a therapeutic strategy. J Immunother 14:298-304.
18. 18. Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptibility to lysis. II. evaluation of tumor infiltrating lymphocytes. J Immunol 142:1767-1773.
19. 19. Miyatake S, Nishihara K, Kikuchi H, Yamashita J, Namba Y, Hanaoka M, Watanabe Y (1990) Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with IFN-gamma gene. J Natl Cancer Inst 82:217-220.
20. 20. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R (1994) IL-10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180:2371-2376.
21. 21. Schendel, D.J. and Gansbacher, B. (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with IL-2 cDNA and exogenous alpha Interferon treatment. Cancer Res 53:4020-4025.
22. 22. Tsai S, Gansbacher B, Tait L, Miller F, Heppner G (1993) Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 85:546-553.
23. 23. Ramsden L, Rider CC (1992) Selective and differential binding of IL-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 22:3027-3031.
24. 24. Eccles S, Heckford S, Alexander P (1980) Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours. Br J Cancer 42:252-259.
25. 25. Gillis S, Smith K (1977) Long term culture of tumour-specific cytotoxic T cells. Nature 268:154-156.